{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:19:39Z","timestamp":1778656779131,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1746-1596-9-48","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T09:04:13Z","timestamp":1393923853000},"source":"Crossref","is-referenced-by-count":7,"title":["Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer"],"prefix":"10.1186","volume":"9","author":[{"given":"Angela","family":"Fuchs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas C","family":"Heukamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Fassunke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jutta","family":"Kirfel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Huss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert J","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Majores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,4]]},"reference":[{"key":"942_CR1","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/jnci\/66.6.1192","volume":"66","author":"R Doll","year":"1981","unstructured":"Doll R, Peto R: The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981, 66: 1191-1308.","journal-title":"J Natl Cancer Inst"},{"key":"942_CR2","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1634\/theoncologist.2008-0207","volume":"13","author":"SN Pinchot","year":"2008","unstructured":"Pinchot SN, Holen K, Sippel RS, Chen H: Carcinoid tumors. Oncologist. 2008, 13: 1255-1269. 10.1634\/theoncologist.2008-0207.","journal-title":"Oncologist"},{"key":"942_CR3","first-page":"10","volume-title":"Pathology and Genetics of Tumours of the Lung Pleura Thymus and Heart","author":"WD Travis","year":"2004","unstructured":"Travis WD, Brambilla E, M\u00fcller-Hermelink HK, Harris CC: Tumours of the lung. Pathology and Genetics of Tumours of the Lung Pleura Thymus and Heart. 2004, Geneva: WHO Press, 10-12."},{"key":"942_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/PPO.0b013e31823e701a","volume":"17","author":"JE Larsen","year":"2011","unstructured":"Larsen JE, Cascone T, Gerber DE, Heymach JV, Minna JD: Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J. 2011, 17: 512-527. 10.1097\/PPO.0b013e31823e701a.","journal-title":"Cancer J"},{"key":"942_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00108-010-2698-y","volume":"52","author":"LC Heukamp","year":"2011","unstructured":"Heukamp LC, Wolf J, Buttner R: [Molecular diagnostics of lung cancer for treatment stratification]. Internist (Berl). 2011, 52: 146-10.1007\/s00108-010-2698-y. 148\u2013150, 152\u2013144","journal-title":"Internist (Berl)"},{"key":"942_CR6","first-page":"403","volume":"79","author":"RE Sobol","year":"1987","unstructured":"Sobol RE, Astarita RW, Hofeditz C, Masui H, Fairshter R, Royston I, Mendelsohn J: Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst. 1987, 79: 403-407.","journal-title":"J Natl Cancer Inst"},{"key":"942_CR7","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1158\/1078-0432.CCR-06-3043","volume":"13","author":"E Massarelli","year":"2007","unstructured":"Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba : KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res. 2007, 13: 2890-2896. 10.1158\/1078-0432.CCR-06-3043.","journal-title":"Clin Cancer Res"},{"key":"942_CR8","first-page":"1314","volume":"7","author":"V Papadimitrakopoulou","year":"2012","unstructured":"Papadimitrakopoulou V: Development of Pi3k\/Akt\/Mtor pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol. 2012, 7: 1314-1326.","journal-title":"J Thorac Oncol"},{"key":"942_CR9","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009, 9: 550-562. 10.1038\/nrc2664.","journal-title":"Nat Rev Cancer"},{"key":"942_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/1746-1596-7-146","volume":"7","author":"C Otto","year":"2012","unstructured":"Otto C, Csanadi A, Fisch P, Werner M, Kayser G: Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer. Diagn Pathol. 2012, 7: 146-10.1186\/1746-1596-7-146.","journal-title":"Diagn Pathol"},{"key":"942_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1746-1596-8-27","volume":"8","author":"Y Xiong","year":"2013","unstructured":"Xiong Y, Bai Y, Leong N, Laughlin TS, Rothberg PG, Xu H, Nong L, Zhao J, Dong Y, Li T: Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies. Diagn Pathol. 2013, 8: 27-10.1186\/1746-1596-8-27.","journal-title":"Diagn Pathol"},{"key":"942_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1383-5742(01)00058-8","volume":"488","author":"M Hengstschlager","year":"2001","unstructured":"Hengstschlager M, Rodman DM, Miloloza A, Hengstschlager-Ottnad E, Rosner M, Kubista M: Tuberous sclerosis gene products in proliferation control. Mutat Res. 2001, 488: 233-239. 10.1016\/S1383-5742(01)00058-8.","journal-title":"Mutat Res"},{"key":"942_CR13","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMra055323","volume":"355","author":"PB Crino","year":"2006","unstructured":"Crino PB, Nathanson KL, Henske EP: The tuberous sclerosis complex. N Engl J Med. 2006, 355: 1345-1356. 10.1056\/NEJMra055323.","journal-title":"N Engl J Med"},{"key":"942_CR14","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000327565","volume":"29","author":"M Kudo","year":"2011","unstructured":"Kudo M: mTOR inhibitor for the treatment of hepatocellular carcinoma. Dig Dis. 2011, 29: 310-315. 10.1159\/000327565.","journal-title":"Dig Dis"},{"issue":"Suppl 3","key":"942_CR15","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/j.seminoncol.2009.10.011","volume":"36","author":"JJ Gibbons","year":"2009","unstructured":"Gibbons JJ, Abraham RT, Yu K: Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol. 2009, 36 (Suppl 3): S3-S17.","journal-title":"Semin Oncol"},{"key":"942_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1042\/bst0310597","volume":"31","author":"MA Knowles","year":"2003","unstructured":"Knowles MA, Hornigold N, Pitt E: Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours. Biochem Soc Trans. 2003, 31: 597-602.","journal-title":"Biochem Soc Trans"},{"key":"942_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.mrrev.2006.03.001","volume":"613","author":"M Rosner","year":"2006","unstructured":"Rosner M, Freilinger A, Hengstschlager M: The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27. Mutat Res. 2006, 613: 10-16. 10.1016\/j.mrrev.2006.03.001.","journal-title":"Mutat Res"},{"key":"942_CR18","first-page":"159","volume":"2001","author":"K Takamochi","year":"1941\u20131948","unstructured":"Takamochi K, Ogura T, Suzuki K, Kawasaki H, Kurashima Y, Yokose T, Ochiai A, Nagai K, Nishiwaki Y, Esumi H: Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung. Am J Pathol. 1941\u20131948, 2001: 159-","journal-title":"Am J Pathol"},{"key":"942_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.lungcan.2004.05.001","volume":"46","author":"K Takamochi","year":"2004","unstructured":"Takamochi K, Ogura T, Yokose T, Ochiai A, Nagai K, Nishiwaki Y, Suzuki K, Esumi H: Molecular analysis of the TSC1 gene in adenocarcinoma of the lung. Lung Cancer. 2004, 46: 271-281. 10.1016\/j.lungcan.2004.05.001.","journal-title":"Lung Cancer"},{"key":"942_CR20","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/onc.2009.452","volume":"29","author":"MC Liang","year":"2010","unstructured":"Liang MC, Ma J, Chen L, Kozlowski P, Qin W, Li D, Goto J, Shimamura T, Hayes DN, Meyerson M, Kwiatkowski DJ, Wong KK: TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene. 2010, 29: 1588-1597. 10.1038\/onc.2009.452.","journal-title":"Oncogene"},{"key":"942_CR21","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00432-008-0509-9","volume":"135","author":"S Zimmer","year":"2009","unstructured":"Zimmer S, Kahl P, Buhl TM, Steiner S, Wardelmann E, Merkelbach-Bruse S, Buettner R, Heukamp LC: Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. J Cancer Res Clin Oncol. 2009, 135: 723-730. 10.1007\/s00432-008-0509-9.","journal-title":"J Cancer Res Clin Oncol"},{"key":"942_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1046\/j.0305-1846.2001.00302.x","volume":"27","author":"AJ Becker","year":"2001","unstructured":"Becker AJ, Lobach M, Klein H, Normann S, Nothen MM, von Deimling A, Mizuguchi M, Elger CE, Schramm J, Wiestler OD, Blumcke I: Mutational analysis of TSC1 and TSC2 genes in gangliogliomas. Neuropathol Appl Neurobiol. 2001, 27: 105-114. 10.1046\/j.0305-1846.2001.00302.x.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"942_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/nar\/21.1.173","volume":"21","author":"A Rosenthal","year":"1993","unstructured":"Rosenthal A, Coutelle O, Craxton M: Large-scale production of DNA sequencing templates by microtitre format PCR. Nucleic Acids Res. 1993, 21: 173-174. 10.1093\/nar\/21.1.173.","journal-title":"Nucleic Acids Res"},{"key":"942_CR24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","volume":"12","author":"GJ Riely","year":"2006","unstructured":"Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006, 12: 839-844. 10.1158\/1078-0432.CCR-05-1846.","journal-title":"Clin Cancer Res"},{"key":"942_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0272-5231(03)00057-1","volume":"23","author":"KS Bilello","year":"2002","unstructured":"Bilello KS, Murin S, Matthay RA: Epidemiology, etiology, and prevention of lung cancer. Clin Chest Med. 2002, 23: 1-25. 10.1016\/S0272-5231(03)00057-1.","journal-title":"Clin Chest Med"},{"key":"942_CR26","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/JTO.0b013e31825581bd","volume":"7","author":"S Ekman","year":"2012","unstructured":"Ekman S, Wynes MW, Hirsch FR: The mTOR pathway in lung cancer and implications for therapy and biomarker analysis. J Thorac Oncol. 2012, 7: 947-953. 10.1097\/JTO.0b013e31825581bd.","journal-title":"J Thorac Oncol"},{"key":"942_CR27","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1158\/1078-0432.CCR-05-1362","volume":"12","author":"E Conde","year":"2006","unstructured":"Conde E, Angulo B, Tang M, Morente M, Torres-Lanzas J, Lopez-Encuentra A, Lopez-Rios F, Sanchez-Cespedes M: Molecular context of the EGFR mutations: evidence for the activation of mTOR\/S6K signaling. Clin Cancer Res. 2006, 12: 710-717. 10.1158\/1078-0432.CCR-05-1362.","journal-title":"Clin Cancer Res"},{"key":"942_CR28","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/311483a0","volume":"311","author":"J Downward","year":"1984","unstructured":"Downward J, Parker P, Waterfield MD: Autophosphorylation sites on the epidermal growth factor receptor. Nature. 1984, 311: 483-485. 10.1038\/311483a0.","journal-title":"Nature"},{"key":"942_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0014-4827(02)00098-8","volume":"284","author":"RN Jorissen","year":"2003","unstructured":"Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003, 284: 31-53. 10.1016\/S0014-4827(02)00098-8.","journal-title":"Exp Cell Res"},{"key":"942_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1746-1596-8-166","volume":"8","author":"S Zheng","year":"2013","unstructured":"Zheng S, Du Y, Chu H, Chen X, Li P, Wang Y, Ma Y, Wang H, Zang W, Zhang G, Zhao G: Analysis of MAT3 gene expression in NSCLC. Diagn Pathol. 2013, 8: 166-10.1186\/1746-1596-8-166.","journal-title":"Diagn Pathol"},{"key":"942_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/1746-1596-7-165","volume":"7","author":"R Beljan Perak","year":"2012","unstructured":"Beljan Perak R, Durdov MG, Capkun V, Ivcevic V, Pavlovic A, Soljic V, Peric M: IMP3 can predict aggressive behaviour of lung adenocarcinoma. Diagn Pathol. 2012, 7: 165-10.1186\/1746-1596-7-165.","journal-title":"Diagn Pathol"},{"key":"942_CR32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/JTO.0b013e3181ce6604","volume":"5","author":"T Dhillon","year":"2010","unstructured":"Dhillon T, Mauri FA, Bellezza G, Cagini L, Barbareschi M, North BV, Seckl MJ: Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer. J Thorac Oncol. 2010, 5: 314-319. 10.1097\/JTO.0b013e3181ce6604.","journal-title":"J Thorac Oncol"},{"key":"942_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1600-0714.2011.01083.x","volume":"41","author":"M Lionello","year":"2012","unstructured":"Lionello M, Blandamura S, Loreggian L, Ottaviano G, Giacomelli L, Marchese-Ragona R, Velardita C, Staffieri A, Marioni G: High mTOR expression is associated with a worse oncological outcome in laryngeal carcinoma treated with postoperative radiotherapy: a pilot study. J Oral Pathol Med. 2012, 41: 136-140. 10.1111\/j.1600-0714.2011.01083.x.","journal-title":"J Oral Pathol Med"},{"key":"942_CR34","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.4161\/cc.10.22.18329","volume":"10","author":"JH Back","year":"2011","unstructured":"Back JH, Kim AL: The expanding relevance of nuclear mTOR in carcinogenesis. Cell Cycle. 2011, 10: 3849-3852. 10.4161\/cc.10.22.18329.","journal-title":"Cell Cycle"},{"key":"942_CR35","doi-asserted-by":"publisher","first-page":"7357","DOI":"10.1074\/jbc.M512218200","volume":"281","author":"RA Bachmann","year":"2006","unstructured":"Bachmann RA, Kim JH, Wu AL, Park IH, Chen J: A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1. J Biol Chem. 2006, 281: 7357-7363. 10.1074\/jbc.M512218200.","journal-title":"J Biol Chem"},{"key":"942_CR36","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/modpathol.2011.121","volume":"24","author":"J Liu","year":"2011","unstructured":"Liu J, Brown RE: Morphoproteomics demonstrates activation of mammalian target of rapamycin pathway in papillary thyroid carcinomas with nuclear translocation of MTOR in aggressive histological variants. Mod Pathol. 2011, 24: 1553-1559. 10.1038\/modpathol.2011.121.","journal-title":"Mod Pathol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1746-1596-9-48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T19:29:49Z","timestamp":1548098989000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/1746-1596-9-48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,4]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["942"],"URL":"https:\/\/doi.org\/10.1186\/1746-1596-9-48","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,4]]},"article-number":"48"}}